Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1799 results
April 2020
-
Featured NewsNovartis Financial Results – Q1 2020
Novartis announced the company’s financial results for the first quarter of 2020.
-
StatementNovartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia
-
Key ReleaseNovartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz: Key growth drivers include Entresto USD 569…
-
Key ReleaseNovartis setzt im 1. Quartal die starke operative Performance fort, bestätigt derzeit die Prognose 2020 und fördert verschiedenste Aktivitäten, um globale Massnahmen gegen COVID-19 zu unterstützenDer Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt im ersten Quartal 2020 um 13% (kWk2, +11% USD) mit zweistelligen Zuwächsen (kWk) bei Innovative Medicines und Sandoz: Zu den…
-
Key ReleaseNovartis conserve une forte performance opérationnelle au 1er trimestre, confirme à ce stade les prévisions pour 2020 et fournit de grands efforts pour contribuer à la réponse mondiale au Covid-19Au 1er trimestre 2020, chiffre d’affaires net des activités poursuivies1 en hausse de 13% (tcc2, +11% USD) avec une croissance à deux chiffres (tcc) d’Innovative Medicines et de Sandoz: Les…
-
A visual tour of scientific strategies for combating coronavirus
Researchers around the world are collaborating to provide solutions to immediate and future challenges.
-
StatementNovartis announces flexible return to office and on-site field activities, starting May 11, 2020
-
Media ReleaseNovartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host diseaseData from Phase III REACH2 study, published in The New England Journal of Medicine, demonstrate Jakavi can improve outcomes for patients with acute graft-versus-host disease (GvHD) who do not respond…
-
Media ReleaseNovartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphomaIf approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults…
-
Media ReleaseAveXis Community Statement on the Coronavirus Disease (COVID-19)Dear SMA Community, Like many organizations across the United States and around the world, AveXis is closely monitoring the coronavirus disease (COVID-19) and its impact on patients, the SMA…
-
Media ReleaseNovartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed…
-
Featured NewsWorld Malaria Day 2020
This year, World Malaria Day is happening as countries around the world are fighting the COVID-19 pandemic.
Pagination
- ‹ Previous page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- …
- 150
- › Next page